Kodiak Sciences Inc. Announces Launch of Initial Public Offering

Palo Alto, CA, September 24, 2018 – Kodiak Sciences Inc. (“Kodiak”) today announced that it has launched an initial public offering of 9,000,000 shares of its common stock at an anticipated initial offering price between $13.00 and $15.00 per share pursuant to a registration statement on Form S-1 (the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (the “SEC”). In addition, Kodiak intends to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of Kodiak’s common stock at the initial public offering price, less underwriting discounts and commissions. Kodiak has applied to list the shares on the Nasdaq Global Market under the ticker symbol “KOD.”

Morgan Stanley and BofA Merrill Lynch are acting as joint book-running managers for the proposed offering. Barclays is also acting as a book-running manager for the offering. Chardan will act as lead manager.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Media Inquiries

Contact

Name:

Email:

Subject:

Message:

Disclaimer

Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.